A rapid rise followed by a national halt

An experimental operation promoted in China as a potential treatment for Alzheimer’s disease was halted nationally after it had spread far beyond the small studies that initially suggested it might help some patients. The procedure, deep cervical lymphaticovenous anastomosis, creates microscopic connections between lymphatic vessels or lymph nodes in the neck and nearby veins.

It is not brain surgery, despite some descriptions of it as an “Alzheimer’s surgery”. Surgeons operate in the deep neck, aiming to alter drainage routes associated with the lymphatic system. Its proposed purpose is to improve the removal of substances from the brain, including proteins implicated in Alzheimer’s disease. That biological rationale drew attention because research into the brain’s fluid-clearance and lymphatic systems has become an important area of neuroscience.

But a plausible mechanism is not the same as a demonstrated treatment. On July 8, 2025, China’s National Health Commission published a notice banning the procedure’s clinical use for Alzheimer’s disease. The notice said the method remained at an early exploratory stage, with unclear indications and contraindications, and without high-quality evidence establishing either its safety or effectiveness. It instructed medical institutions to stop using it as treatment and to provide follow-up care for affected patients.

The scale of use made the decision unusually consequential. Public reports and later academic assessments indicated that hundreds of hospitals had offered variants of the operation, while a proposed registry was designed around hundreds of previous recipients. This supports the broad conclusion that the procedure had been performed on a substantial number of people, although a precise nationwide total has not been independently established in the public record.

Why the operation seemed promising

Alzheimer’s disease is a progressive neurodegenerative condition associated with memory loss and declining cognitive function. Its defining pathology includes the accumulation of amyloid-beta protein and tau abnormalities in the brain. Modern drug development has increasingly targeted these processes, but available treatments do not cure the disease and their benefits, eligibility requirements and risks remain limited.

That backdrop helps explain the appeal of a one-time surgical intervention. The brain is now known to have pathways through which fluid, immune cells and metabolic waste can move toward lymphatic drainage routes outside the skull. Researchers have proposed that impaired clearance could contribute to the build-up of damaging proteins in Alzheimer’s disease.

Deep cervical lymphaticovenous anastomosis is intended to bypass or relieve resistance in these drainage routes by connecting lymphatic structures to veins. Proponents have argued that improving outflow in the neck could support removal of fluid and waste products from the central nervous system. The hypothesis is scientifically interesting, but it contains several steps that must each be demonstrated: that lymphatic drainage is meaningfully impaired in the relevant patients, that the operation reliably changes it, that the change persists, and that it produces a clinically important slowing of disease rather than a short-term or subjective improvement.

Those questions have not yet been answered by robust trials. A 2025 prospective study of 26 patients reported favourable cognitive results after surgery, but it was a single-centre, single-arm exploratory study. Without random allocation, a comparison group or blinded assessment, such work cannot reliably separate a surgical effect from variation in symptoms, practice effects on cognitive tests, selection of patients, concurrent care or caregiver expectations.

The evidence gap is especially important in surgery

The normal standard for a treatment intended for wide clinical use is not simply evidence that it can be performed. It must also show that benefits outweigh harms compared with appropriate alternatives. This is particularly important for an invasive procedure given to older people who may have frailty, cardiovascular disease, swallowing or airway risks, and cognitive impairment that can complicate consent and recovery.

Reviews of the available evidence have identified mostly case reports, small observational series and uncontrolled studies. They also note unresolved technical questions. Researchers have not consistently verified whether the newly created connections remain open, whether fluid travels in the intended direction, or whether the procedure measurably improves the brain-clearance processes invoked to justify it.

The distinction matters because anatomical success does not guarantee clinical success. Even if a surgeon can create a patent connection between a lymphatic structure and a vein, it does not necessarily follow that the operation changes Alzheimer’s pathology or improves daily function over months and years. The disease advances slowly and variably, so claims of benefit need durable follow-up and measures that matter to patients and families, not only changes in a single cognitive score.

There is also a wider methodological challenge. Surgical trials are difficult to conduct because blinding is harder than in drug studies and sham surgery can raise ethical concerns. Yet those difficulties make careful trial design more necessary, not less. Independent outcome assessment, predefined endpoints, transparent adverse-event reporting and appropriate control groups are all needed before the procedure can be judged fairly.

A ban that leaves room for research

China’s decision was not a declaration that the underlying lymphatic hypothesis is impossible. The National Health Commission explicitly left a route for further research: institutions could pursue properly designed clinical studies after sufficient preclinical evidence and ethical review, with the regulator able to reconsider clinical application in light of new evidence.

That approach draws an essential boundary between research and treatment. In research, uncertainty is disclosed, participant safeguards are strengthened and a protocol is designed to generate reliable knowledge. In routine treatment, patients and families may reasonably assume that a procedure has an established balance of benefit and risk. The rapid uptake of the neck operation blurred those categories.

Registered studies indicate that researchers had begun to plan larger investigations, including multicentre comparisons of surgery plus medication against medication alone. Such trials could help determine whether the apparent benefits seen in early reports are reproducible. They should also examine which patients, if any, might benefit, whether biomarker-confirmed Alzheimer’s disease responds differently from other causes of dementia, and how the operation compares with best available medical and supportive care.

A test of evidence-based innovation

The episode is a reminder that desperation can accelerate medical adoption. Alzheimer’s disease imposes immense burdens on patients, carers and health systems, and families facing progressive decline are understandably receptive to interventions that offer hope. Rapid innovation can be valuable, especially where existing options are inadequate. But enthusiasm must be matched by evidence proportionate to the intervention’s risks and claims.

For now, the surgery should be regarded as an unproven research idea rather than an Alzheimer’s treatment. Its scientific premise deserves rigorous examination, but the national suspension reflects a basic principle of clinical medicine: a promising theory and encouraging early observations are not enough to justify widespread invasive care. The unanswered question is no longer whether the procedure can attract interest. It is whether it can meet the evidentiary standard required to earn patients’ trust.

Sources